Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

Antonio Russo, Antonio Galvano, Francesco Passiglia, Francesco Pantano, Tindara Franchina, Olga Venditti, Fausto Petrelli, Enrico Vasile, Andrea Napolitano, Silvia Quadrini, Salvatore Intagliata, Daniela Iacono, Marco Imperatori, Lorenzo Calvetti, Elisa Roca, Marco Russano, Daniela Iacono, Alessandro Russo, Iacopo Fioroni, Giulia PasquiniMichele Aieta, Mario A. Occhipinti, Luana Calabrò, Alessio Cortellini, Alfredo Berruti, Olga Martelli, Giuseppe Aprile, Maria R. Migliorino, Corrado Ficorella, Bruno Vincenzi, Vincenzo Adamo, Giovanni Mansueto, Alfredo Falcone, Alfredo Berruti, Michele Maio, Giuseppe Tonini, Sandro Barni, Daniele Santini, Anna M. Di Giacomo, Alain Gelibter, Antonio Venditti, Elena Procaccianti

Risultato della ricerca: Articlepeer review

1 Citazioni (Scopus)

Abstract

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications.
Lingua originaleEnglish
pagine (da-a)319-326
Numero di pagine8
RivistaExpert Opinion on Biological Therapy
Volume20
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Entra nei temi di ricerca di 'Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab'. Insieme formano una fingerprint unica.

Cita questo